NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma NIVO + LAG-3 Antibody Succeeds in Advanced Melanoma

ASCO studies validate dual LAG-3 and PD-1 inhibition in advanced melanoma, with good tolerability profiles, says Jeffrey Weber.Medscape Oncology

Source: Medscape Today Headlines - July 1, 2021 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news